Cargando…
Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?
Chimeric antigen receptor T-cells (CAR-Ts) are known as revolutionary living drugs that have turned the tables of conventional cancer treatments in certain hematologic malignancies such as B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) by achieving US Food and...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130586/ https://www.ncbi.nlm.nih.gov/pubmed/35634281 http://dx.doi.org/10.3389/fimmu.2022.795164 |
_version_ | 1784713004440354816 |
---|---|
author | Safarzadeh Kozani, Pouya Safarzadeh Kozani, Pooria Ahmadi Najafabadi, Milad Yousefi, Fatemeh Mirarefin, Seyed Mohamad Javad Rahbarizadeh, Fatemeh |
author_facet | Safarzadeh Kozani, Pouya Safarzadeh Kozani, Pooria Ahmadi Najafabadi, Milad Yousefi, Fatemeh Mirarefin, Seyed Mohamad Javad Rahbarizadeh, Fatemeh |
author_sort | Safarzadeh Kozani, Pouya |
collection | PubMed |
description | Chimeric antigen receptor T-cells (CAR-Ts) are known as revolutionary living drugs that have turned the tables of conventional cancer treatments in certain hematologic malignancies such as B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) by achieving US Food and Drug Administration (FDA) approval based on their successful clinical outcomes. However, this type of therapy has not seen the light of victory in the fight against solid tumors because of various restricting caveats including heterogeneous tumor antigen expression and the immunosuppressive tumor microenvironments (TME) that negatively affect the tumor-site accessibility, infiltration, stimulation, activation, and persistence of CAR-Ts. In this review, we explore strategic twists including boosting vaccines and designing implementations that can support CAR-T expansion, proliferation, and tumoricidal capacity. We also step further by underscoring novel strategies for triggering endogenous antitumor responses and overcoming the limitation of poor CAR-T tumor-tissue infiltration and the lack of definitive tumor-specific antigens. Ultimately, we highlight how these approaches can address the mentioned arduous hurdles. |
format | Online Article Text |
id | pubmed-9130586 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91305862022-05-26 Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero? Safarzadeh Kozani, Pouya Safarzadeh Kozani, Pooria Ahmadi Najafabadi, Milad Yousefi, Fatemeh Mirarefin, Seyed Mohamad Javad Rahbarizadeh, Fatemeh Front Immunol Immunology Chimeric antigen receptor T-cells (CAR-Ts) are known as revolutionary living drugs that have turned the tables of conventional cancer treatments in certain hematologic malignancies such as B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) by achieving US Food and Drug Administration (FDA) approval based on their successful clinical outcomes. However, this type of therapy has not seen the light of victory in the fight against solid tumors because of various restricting caveats including heterogeneous tumor antigen expression and the immunosuppressive tumor microenvironments (TME) that negatively affect the tumor-site accessibility, infiltration, stimulation, activation, and persistence of CAR-Ts. In this review, we explore strategic twists including boosting vaccines and designing implementations that can support CAR-T expansion, proliferation, and tumoricidal capacity. We also step further by underscoring novel strategies for triggering endogenous antitumor responses and overcoming the limitation of poor CAR-T tumor-tissue infiltration and the lack of definitive tumor-specific antigens. Ultimately, we highlight how these approaches can address the mentioned arduous hurdles. Frontiers Media S.A. 2022-05-11 /pmc/articles/PMC9130586/ /pubmed/35634281 http://dx.doi.org/10.3389/fimmu.2022.795164 Text en Copyright © 2022 Safarzadeh Kozani, Safarzadeh Kozani, Ahmadi Najafabadi, Yousefi, Mirarefin and Rahbarizadeh https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Safarzadeh Kozani, Pouya Safarzadeh Kozani, Pooria Ahmadi Najafabadi, Milad Yousefi, Fatemeh Mirarefin, Seyed Mohamad Javad Rahbarizadeh, Fatemeh Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero? |
title | Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero? |
title_full | Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero? |
title_fullStr | Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero? |
title_full_unstemmed | Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero? |
title_short | Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero? |
title_sort | recent advances in solid tumor car-t cell therapy: driving tumor cells from hero to zero? |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130586/ https://www.ncbi.nlm.nih.gov/pubmed/35634281 http://dx.doi.org/10.3389/fimmu.2022.795164 |
work_keys_str_mv | AT safarzadehkozanipouya recentadvancesinsolidtumorcartcelltherapydrivingtumorcellsfromherotozero AT safarzadehkozanipooria recentadvancesinsolidtumorcartcelltherapydrivingtumorcellsfromherotozero AT ahmadinajafabadimilad recentadvancesinsolidtumorcartcelltherapydrivingtumorcellsfromherotozero AT yousefifatemeh recentadvancesinsolidtumorcartcelltherapydrivingtumorcellsfromherotozero AT mirarefinseyedmohamadjavad recentadvancesinsolidtumorcartcelltherapydrivingtumorcellsfromherotozero AT rahbarizadehfatemeh recentadvancesinsolidtumorcartcelltherapydrivingtumorcellsfromherotozero |